177 related articles for article (PubMed ID: 30824387)
1. Attributable mortality from extensively drug-resistant gram-negative infections using propensity-matched tracer antibiotic algorithms.
Kadri SS; Strich JR; Swihart BJ; Hohmann S; Dekker JP; Palmore T; Bonne S; Freeman B; Raybould J; Shah NG; Patel D; Husson J; Jacobs MD; Duong L; Follmann D; Hooper DC; Timpone J; Danner RL
Am J Infect Control; 2019 Sep; 47(9):1040-1047. PubMed ID: 30824387
[TBL] [Abstract][Full Text] [Related]
2. Attributable clinical and economic burden of carbapenem-non-susceptible Gram-negative infections in patients hospitalized with complicated urinary tract infections.
Tabak YP; Sung AH; Ye G; Vankeepuram L; Gupta V; McCann E
J Hosp Infect; 2019 May; 102(1):37-44. PubMed ID: 30503367
[TBL] [Abstract][Full Text] [Related]
3. The impact of carbapenem resistance on clinical deterioration and mortality in patients with liver disease.
Ferstl PG; Filmann N; Brandt C; Zeuzem S; Hogardt M; Kempf VAJ; Müller M; Waidmann O; Reinheimer C
Liver Int; 2017 Oct; 37(10):1488-1496. PubMed ID: 28374901
[TBL] [Abstract][Full Text] [Related]
4. Attributable burden in patients with carbapenem-nonsusceptible gram-negative respiratory infections.
Tabak YP; Sung A; Ye G; Vankeepuram L; Gupta V; McCann E
PLoS One; 2020; 15(2):e0229393. PubMed ID: 32084236
[TBL] [Abstract][Full Text] [Related]
5. The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study.
Zak-Doron Y; Dishon Benattar Y; Pfeffer I; Daikos GL; Skiada A; Antoniadou A; Durante-Mangoni E; Andini R; Cavezza G; Leibovici L; Yahav D; Eliakim-Raz N; Carmeli Y; Nutman A; Paul M;
Clin Infect Dis; 2018 Nov; 67(12):1815-1823. PubMed ID: 29718143
[TBL] [Abstract][Full Text] [Related]
6. Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study.
Strich JR; Warner S; Lai YL; Demirkale CY; Powers JH; Danner RL; Kadri SS
Lancet Infect Dis; 2020 Oct; 20(10):1172-1181. PubMed ID: 32505231
[TBL] [Abstract][Full Text] [Related]
7. Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant Gram-negative infections.
Kadri SS; Hohmann SF; Orav EJ; Bonne SL; Moffa MA; Timpone JG; Strich JR; Palmore T; Christopher KB; Varughese C; Hooper DC; Danner RL
Clin Infect Dis; 2015 Jan; 60(1):79-87. PubMed ID: 25246597
[TBL] [Abstract][Full Text] [Related]
8. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents.
Kadri SS; Adjemian J; Lai YL; Spaulding AB; Ricotta E; Prevots DR; Palmore TN; Rhee C; Klompas M; Dekker JP; Powers JH; Suffredini AF; Hooper DC; Fridkin S; Danner RL;
Clin Infect Dis; 2018 Nov; 67(12):1803-1814. PubMed ID: 30052813
[TBL] [Abstract][Full Text] [Related]
9. Predicting acquisition of carbapenem-resistant Gram-negative pathogens in intensive care units.
Dantas LF; Dalmas B; Andrade RM; Hamacher S; Bozza FA
J Hosp Infect; 2019 Oct; 103(2):121-127. PubMed ID: 31039381
[TBL] [Abstract][Full Text] [Related]
10. Impact of extended-spectrum β-lactamases and carbapenem-resistant Gram-negative infections on sepsis mortality at the emergency department: a cohort study.
Sabino S; Monroy H; Jara C; Lopez O; Ramos F; Falci DR; Rigatto MH
J Hosp Infect; 2019 Feb; 101(2):190-191. PubMed ID: 29792969
[No Abstract] [Full Text] [Related]
11. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria.
Pintado V; San Miguel LG; Grill F; Mejía B; Cobo J; Fortún J; Martín-Dávila P; Moreno S
J Infect; 2008 Mar; 56(3):185-90. PubMed ID: 18280570
[TBL] [Abstract][Full Text] [Related]
12. Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study.
Andria N; Henig O; Kotler O; Domchenko A; Oren I; Zuckerman T; Ofran Y; Fraser D; Paul M
J Antimicrob Chemother; 2015 Nov; 70(11):3146-53. PubMed ID: 26209312
[TBL] [Abstract][Full Text] [Related]
13. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043
[TBL] [Abstract][Full Text] [Related]
14. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.
Nørgaard SM; Jensen CS; Aalestrup J; Vandenbroucke-Grauls CMJE; de Boer MGJ; Pedersen AB
Antimicrob Resist Infect Control; 2019; 8():170. PubMed ID: 31709047
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: A retrospective propensity-matched case control study.
Ting SW; Lee CH; Liu JW
J Microbiol Immunol Infect; 2018 Oct; 51(5):621-628. PubMed ID: 28732563
[TBL] [Abstract][Full Text] [Related]
16. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
[TBL] [Abstract][Full Text] [Related]
17. Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with Gram-negative bacteremia.
Micek ST; Welch EC; Khan J; Pervez M; Doherty JA; Reichley RM; Hoppe-Bauer J; Dunne WM; Kollef MH
J Hosp Med; 2011 Sep; 6(7):405-10. PubMed ID: 21916003
[TBL] [Abstract][Full Text] [Related]
18. Influence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative Bacilli.
Gibson GA; Bauer SR; Neuner EA; Bass SN; Lam SW
Antimicrob Agents Chemother; 2016 Jan; 60(1):431-6. PubMed ID: 26525802
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME
Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915
[TBL] [Abstract][Full Text] [Related]
20. Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis.
Johnson MT; Reichley R; Hoppe-Bauer J; Dunne WM; Micek S; Kollef M
Crit Care Med; 2011 Aug; 39(8):1859-65. PubMed ID: 21499086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
